CRISPR Therapeutics AG (NASDAQ:CRSP) Given Consensus Recommendation of “Hold” by Brokerages

CRISPR Therapeutics AG (NASDAQ:CRSP) has earned an average recommendation of “Hold” from the twenty-one analysts that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, nine have assigned a hold recommendation and eleven have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $73.11.

Several equities research analysts recently issued reports on CRSP shares. HC Wainwright reiterated a “buy” rating and issued a $65.00 price objective on shares of CRISPR Therapeutics in a report on Thursday, February 13th. JMP Securities reiterated a “market outperform” rating and set a $86.00 price target on shares of CRISPR Therapeutics in a research note on Thursday, February 13th. TD Cowen raised shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 price objective for the company in a research note on Wednesday, February 12th. Truist Financial lifted their price objective on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the company a “buy” rating in a report on Wednesday, February 12th. Finally, Citigroup reduced their target price on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a “buy” rating on the stock in a report on Tuesday, February 18th.

Insider Activity at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 18,360 shares of the business’s stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the completion of the sale, the chief executive officer now owns 171,613 shares in the company, valued at approximately $9,473,037.60. The trade was a 9.66 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel James R. Kasinger sold 2,850 shares of the stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $120,897.00. Following the completion of the transaction, the general counsel now directly owns 77,530 shares in the company, valued at $3,288,822.60. This trade represents a 3.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 32,381 shares of company stock valued at $1,608,243 over the last three months. 4.10% of the stock is owned by corporate insiders.

Institutional Trading of CRISPR Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Wood Tarver Financial Group LLC acquired a new stake in shares of CRISPR Therapeutics during the fourth quarter worth about $30,000. Wilmington Savings Fund Society FSB acquired a new stake in CRISPR Therapeutics during the 3rd quarter worth approximately $40,000. Ameriflex Group Inc. purchased a new position in shares of CRISPR Therapeutics in the 4th quarter valued at approximately $36,000. Darwin Wealth Management LLC acquired a new position in shares of CRISPR Therapeutics in the third quarter valued at approximately $43,000. Finally, Highline Wealth Partners LLC acquired a new stake in shares of CRISPR Therapeutics during the fourth quarter worth $39,000. 69.20% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Price Performance

NASDAQ CRSP opened at $43.49 on Thursday. CRISPR Therapeutics has a 12 month low of $36.52 and a 12 month high of $76.86. The stock has a market capitalization of $3.73 billion, a P/E ratio of -9.95 and a beta of 1.77. The firm’s 50-day moving average is $43.02 and its two-hundred day moving average is $45.65.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. As a group, analysts anticipate that CRISPR Therapeutics will post -5.16 EPS for the current year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.